Drug Trial Radar · NCT05475184
A Study to Evaluate the Efficacy and Safety of JPI-547 in Platinum-resistant, Advanced/Relapsed Ovarian Cancer Subjects Previously Treated With a PARP Inhibitor
Last checked: Nov 19, 2026Latest source record: Aug 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
58
Planned (sponsor's estimate)
Start
Aug 31, 2022
Primary completion
Nov 2024
Study completion Jun 2025
Sponsor
- Lead sponsor
- Onconic Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 26, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy and safety of JPI-547, a PARP/TNKS dual inhibitor in Platinum-resistant, advanced/relapsed ovarian cancer subjects previously treated with a PARP inhibitor
Conditions
- Ovarian Cancer
Interventions
JPI-547Drug
Poly-(ADP-ribose) polymerase (PARP) \& tankyrase (TNKS) inhibitor. * The investigational product (IP) will be administered once daily for 28 days (4 weeks) with 1 cycle. * 1 capsule (JPI-547 150 mg) will be administered once daily at the same time (e.g., a fixed time in the morning) in a fasted condition within 2 hours before or after a meal.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate(ORR)Time frame: From date of study enroll until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 40 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Cancer Center
Gyeonggi-do, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.